RBC Optimistic on Regeneron Following Lower Sales by Novartis’ Lucentis
Benzinga
Adnan Butt added that Lucentis growth in non-wet AMD indications outside the U.S. suggests that there is room for Eyelea to expand as it secures other approvals, including diabetic macular edema (DME). The analyst expects to Eyelea to capture more than …

and more

…read more

Source: Wet Macular Degeneration News From Google News

By Zennie Abraham

Zennie Abraham | Zennie Abraham or "Zennie62" is the founder of Zennie62Media which consists of zennie62blog.com and a multimedia blog news aggregator and video network, and 78-blog network, with social media and content development services and consulting. Zennie is a pioneer video blogger, YouTube Partner, social media practitioner, game developer, and pundit. Note: news aggregator content does not reflect the personal views of Mr. Abraham.

Leave a Reply

Your email address will not be published. Required fields are marked *